Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2015 - 2017)

Gyre Therapeutics (GYRE) reported Notes Payables of $5.1 million for Q4 2017, down 73.79% year-over-year from $19.4 million in Q4 2016, and down 7.34% on a QoQ basis from $5.5 million in Q3 2017.

Gyre Therapeutics (GYRE) has 3 years of Notes Payables data on file, last reported at $5.1 million in Q4 2017.

  • Quarterly Notes Payables fell 73.79% year-over-year to $5.1 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $5.1 million (down 73.79% YoY) and the FY2017 annual result came in at $5.1 million, down 73.79% from the prior year.
  • Notes Payables retreated to $5.1 million in Q4 2017 per GYRE's latest filing, from $5.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $34.8 million in Q3 2015 and bottomed at $5.1 million in Q4 2017.
  • The 3-year median for Notes Payables is $24.5 million (2016), against an average of $20.8 million.
  • The widest annual swing landed in 2016, when Notes Payables slipped 14.69%; it then slumped 81.5% in 2017.
  • Tracing GYRE's Notes Payables over 3 years: stood at $33.7 million in 2015, then tumbled by 42.5% to $19.4 million in 2016, then slumped by 73.79% to $5.1 million in 2017.
  • Per Business Quant, the three latest GYRE Notes Payables figures stand at $5.1 million (Q4 2017), $5.5 million (Q3 2017), and $5.8 million (Q2 2017).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 5.09 Mn
Sep 30, 2017 5.49 Mn
Jun 30, 2017 5.77 Mn
Mar 31, 2017 12.65 Mn
Dec 31, 2016 19.40 Mn
Sep 30, 2016 29.67 Mn
Jun 30, 2016 30.34 Mn
Mar 31, 2016 30.94 Mn
Dec 31, 2015 33.74 Mn
Sep 30, 2015 34.78 Mn